The Utility of 68Ga-PSMA PET/CT in Decisions Regarding Administering Salvage Radiotherapy to Men with Prostate Cancer

Jennifer Ben Shimol, Ron Lewin, Zvi Symon, Barak Rosenzweig, Raya Leibowitz-Amit, Yael Eshet, Liran Domachevsky and Tima Davidson ()
Additional contact information
Jennifer Ben Shimol: Barzilai Medical Center, Ashqelon 7830604, Israel
Ron Lewin: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
Zvi Symon: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
Barak Rosenzweig: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
Raya Leibowitz-Amit: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
Yael Eshet: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
Liran Domachevsky: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
Tima Davidson: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel

IJERPH, 2022, vol. 20, issue 1, 1-11

Abstract: Background: Numerous papers have described 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)’s sensitivity in identifying prostate cancer (PCa) recurrence. This study aimed to characterize the role of 68Ga-PSMA PET/CT in deciding to re-irradiate pelvic structures. Methods: 68Ga-PSMA PET/CT scans performed at Sheba Medical Center over seven years in 113 men were reviewed. All had undergone radiation to the prostate (70, 61.9%) or post-radical prostatectomy radiation to the prostate fossa (PF) (43, 48.1%), and had local or oligometastatic PCa recurrence and received salvage radiotherapy (SRT) based on PET/CT findings. Results: Mean age was 70.7 years. The mean grade group was 2.9; the mean prostate-specific antigen was 9.0. The 68Ga-PSMA PET/CT positive findings included: 37 (32.7%) in the prostate, 23 (20.4%) in seminal vesicles, 7 (6.2%) in the PF, and 3 (2.7%) in the seminal vesicle fossa. The mean standardized uptake value was 10.6 ± 10.2 (range: 1.4–61.6); the mean lesion size was 1.8 ± 3.5 mm (range: 0.5–5.1). SRT was directed toward the prostate and seminal vesicles in 48 (42.5%), PF in 18 (15.9%), and intrapelvic lymph node and bone in 47 (41.6%). Toxicities were mostly mild to moderate. Conclusion: 68Ga-PSMA PET/CT-identified relapse with targeted SRT was well-tolerated and may result in less onerous treatments.

Keywords: prostate cancer; salvage therapy; radiation therapy; 68Ga-PSMA; PET-CT (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/20/1/537/pdf (application/pdf)
https://www.mdpi.com/1660-4601/20/1/537/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:20:y:2022:i:1:p:537-:d:1018439

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().